These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9351533)

  • 1. Who should receive recombinant factor VIII?
    Giangrande PL
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic products and difficult decisions. The case of recombinant factor VIII in the management of haemophilia A.
    Green C; Akehurst R
    J Public Health Med; 1998 Jun; 20(2):137-8. PubMed ID: 9675729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 4. Million dollar miracles.
    Smith SD
    Minn Med; 2006 Apr; 89(4):30-5, 51. PubMed ID: 16681280
    [No Abstract]   [Full Text] [Related]  

  • 5. UK: Hemophiliac wins access to recombinant factor VIII.
    Gold J
    Can HIV AIDS Policy Law Rev; 2003 Dec; 8(3):62. PubMed ID: 15108666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Participation in research: the economic advantages in a haemophilia research population.
    Wasserman J; Ullman M; Cantini M; Moynihan K; Hoots WK
    Haemophilia; 2000 Sep; 6(5):571-4. PubMed ID: 11012704
    [No Abstract]   [Full Text] [Related]  

  • 7. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Previously untreated patients and recombinant factor VIII concentrate studies.
    Pasi KJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S29-32. PubMed ID: 9351534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party.
    Hay CR; Colvin BT; Ludlam CA; Hill FG; Preston FE
    Blood Coagul Fibrinolysis; 1996 Mar; 7(2):134-8. PubMed ID: 8735802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychosocial issues surrounding the general or restricted use of recombinant factor VIII: hemophilia clinic perspective.
    McDonald JR
    Transfus Med Rev; 1992 Oct; 6(4):277-9. PubMed ID: 1421829
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A.
    Hay JW; Ernst RL; Kessler CM
    Haemophilia; 1999 May; 5(3):191-202. PubMed ID: 10444287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines on treatment of haemophilia in Sweden.
    Berntorp E
    Haemophilia; 1998 Jul; 4(4):425-6. PubMed ID: 9873768
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment for haemophilia by postcode.
    Ludlam CA; Hay CR; Dolan G
    BMJ; 1997 Mar; 314(7082):749. PubMed ID: 9116559
    [No Abstract]   [Full Text] [Related]  

  • 15. UK Haemophilia Centre Doctors' Organisation guidance on the use of extended-half-life coagulation factor concentrates in routine clinical practice: Report of a meeting on their adoption by Belgian haemophilia treaters.
    Hermans C; Van Damme A; Dolan G; Maes P; Peerlinck K
    Haemophilia; 2018 Sep; 24(5):e378-e380. PubMed ID: 30182454
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of recombinant factor VIII in the management of hemophilia.
    Mannucci PM; Gringeri A
    Ric Clin Lab; 1991; 21(1):1-7. PubMed ID: 1907760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey.
    Peyvandi F; Palla R; Franchi C; Nobili A; Rosendaal FR; Mannucci PM
    Haemophilia; 2018 Jul; 24(4):e266-e268. PubMed ID: 29869363
    [No Abstract]   [Full Text] [Related]  

  • 18. Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada.
    Teitel JM; Card R; Strawczynski H
    Haemophilia; 1998 Sep; 4(5):731-8. PubMed ID: 9873879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National haemophilia treatment protocols: Canada.
    Teitel JM
    Haemophilia; 1998 Jul; 4(4):422-3. PubMed ID: 9873766
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemophilia market awaits next-generation therapies.
    Sheridan C
    Nat Biotechnol; 2011 Nov; 29(11):960. PubMed ID: 22068523
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.